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Abstract 
 
In the last decade, there have been significant advances in the areas of engineering and 
science, allowing the implementation of pharmaceutical continuous manufacturing (CM). 
These advances are coupled with the adoption of the quality by design paradigm for 
pharmaceutical development and the advances on process analytical technology to 
improve design, analysis and control. These advances have contributed significantly to 
advances on the design and manufacturing of pharmaceutical, namely the adoption of 
continuous processing. Continuous manufacturing can be used for the production of 
medicines in multiple pharmaceutical forms. If advances are being operated in the field 
of continuous manufacturing, it is also true that substantial efforts are still required to fully 
understand how this manufacturing paradigm can be efficiently integrated within 
industry, for full advantages to be achieved.  
This work had the objective of pursuing the goal to better understand how materials 
behave under continuous processing. It aimed at evaluating the performance of a direct 
compression process for tablets production in continuous mode. Direct compression, a 
unit operation especially interesting for the manufacturing of tablets, has the ability to be 
efficiently integrated within a continuous manufacturing framework. The investigated 
continuous manufacturing process resourced to the continuous table production line 
located at the PROMIS Center at the School of Pharmacy of the University of Eastern 
Finland (Kuopio, Finland). The line was configured for direct compression purposes, 
encompassing multiple gravimetric feeders, a continuous mixer and a tableting machine. 
Tablets monitoring was accomplished with near-infrared spectroscopy. A formulation 
containing simultaneously caffeine (2.6%) and paracetamol (20%) was selected for this 
study. Selected process variables were varied according to an experimental design in 
order to understand the effects on tablets' properties. Mixer speed (350-1200 rpm), feed 
rate (5-10 kg/h) and the existence or not of premixture were the selected process 
variables. Tablets were evaluated according to the weight, hardness and thickness. 
Feed rate demonstrated as was expected to be fundamental for the stability of the direct 
compression process. For instance, experiments carried out at lower feed rates (lower 
than 5kg/h) revealed poor fluidity and tablets were not acceptable. The influence of 
process variables on tablets properties was modelled by partial least squares regression. 
Tablets mass is significantly affected, in a positive way, by the speed of the mixer and 
negatively affected by the feed rate. The range of coefficients of determination for the 
calibration (R2) and test (Q2) for the three responses were 0.78-0.94 for R2 and 0.56-0.88 
for Q2. Near-infrared spectra collected from tablets allowed the development of PLS 
models for the caffeine and paracetamol content. Validation experiments reveal that the 
root mean square errors of prediction for caffeine and paracetamol were respectively 
11.96% and 10.48%. 
 
Key-words: Continuous manufacturing; Tableting; Process Analytical 
Technology; Chemometrics; Near Infrared Spectroscopy.  
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Resumo 
 
Historicamente, a produção em descontínuo de formas de dosagem sólidas teve grande 
sucesso e dominou a indústria farmacêutica. Durante muito tempo a indústria entendeu 
não haver motivação para inovar no sentido do desenvolvimento de novas tecnologias 
de fabrico, dada a rentabilidade desta forma de produção. No entanto, atualmente, na 
era pós-blockbuster, tendo em conta que os custos dos materiais, durante o 
desenvolvimento de medicamentos, são significativos, que novos medicamentos, 
provavelmente, serão fabricados em quantidades muito menores e que, para novos 
tratamentos, o desenvolvimento de um processo de produção comercial não é 
garantido, é cada vez mais reconhecida a necessidade de novos paradigmas de 
produção. 
A produção em contínuo surge como uma alternativa à produção em (semi-) 
descontínuo e tem por objetivo aumentar a eficácia e a eficiência na produção 
farmacêutica. Esta nova abordagem exige que a indústria farmacêutica, primária e 
secundária, aborde de maneira diferente a forma como desenvolve e otimiza os 
processos de fabrico para produção de substâncias ativas e formulações farmacêuticas. 
É fundamental a compreensão do processo como um todo, bem como inovação ao nível 
empresarial. É crucial entender e minimizar a variabilidade das matérias-primas, 
executar medições contínuas durante o processo, definir uma amostragem 
representativa e caracterizar a propagação de alterações e distúrbios através do 
sistema. Ao contrário da produção em descontínuo, em que o controlo local de cada 
equipamento é considerado suficiente, na produção em contínuo, o controlo local é não 
só obrigatório, como todo o fluxo do processo deve ser coordenado e equipado com 
sistemas de controlo de segundo nível, supervisionando e controlando todas as 
operações unitárias.  Monitorizar e controlar a composição de um produto durante todo 
o seu processo de fabrico, com a finalidade de alcançar a qualidade e robustez 
pretendida, é um importante objetivo a ser alcançado numa produção em modo 
contínuo. 
Um passo importante para a implementação da produção em contínuo foi dado em 
2004, quando a Food and Drug Administration publicou uma diretriz de tecnologias 
analíticas de processo (PAT), que promove a adoção de tecnologias inovadoras para 
realizar medições oportunas em atributos críticos de qualidade de materiais brutos e em 
processo, permitindo alcançar uma melhor compreensão e controlo do processo. O 
conceito PAT está intimamente ligado à ideia do desenho pela qualidade a qual 
considera não apenas a avaliação de risco para a qualidade e o conhecimento sobre o 
processo, mas também a forma como as operações unitárias afetam a qualidade e 
estabilidade do produto. A espectroscopia de infravermelho próximo tem sido utilizada 
como uma ferramenta de controlo PAT. Esta ferramenta de controlo combinada com a 
análise de dados multivariados tornou-se uma ferramenta interessante na análise 
farmacêutica, tanto a nível qualitativo como quantitativo. 
Esta tese foi realizada utilizando a linha de produção contínua de comprimidos do 
PROMIS Centre (Escola de Farmácia, Universidade do Leste da Finlândia) em Kuopio, 
Finlândia. A monitorização do processo foi realizada em tempo real, por um sistema de 
infravermelho próximo com uma câmara espectral SPECIM e um sensor ImSpector 
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(SPECIM, Finlândia). Com o propósito de avaliar o processo de compressão direta em 
modo contínuo foram definidas um conjunto de experiências variando a velocidade do 
misturador (350 a 1200 rpm), fluxo (5 a 10 kg/h). Foi ainda avaliada importância de 
existência de etapa de pré-mistura. Como respostas foram avaliados a massa, dureza 
e espessura dos comprimidos. A análise de componentes principais foi usada como 
método de análise exploratória dos espetros obtidos, assim como para identificar 
medições atípicas. A monitorização da taxa de alimentação, elemento fundamental na 
compressão direta, decorreu sem grandes variações em relação aos set points definidos 
para cada matéria prima. Deste modo, os dados analisados, relativamente à taxa de 
alimentação de cafeína e paracetamol, permitiram perspetivar que as concentrações 
dos mesmos, nos comprimidos seriam as esperadas.  Durante a realização das 
experiências ficou ainda visível que as que tinham uma taxa de alimentação de 5 kg/h, 
evidenciavam uma fraca fluidez, já com valores de 10 kg/h a fluidez melhorava 
significativamente. De acordo com os modelos de regressão múltipla (PLS) para avaliar 
a influência das variáveis alteradas nas respostas selecionadas, a massa de cada 
comprimido é significativamente afetada, de uma forma positiva, pela velocidade do 
misturador e negativamente afetada pela taxa de fluxo. Para além disso, este modelo 
prevê que a dureza seja afetada pela existência ou não de pré-mistura. Para os três 
modelos o R2 não se verificou muito elevado, variando entre 0.78 e 0.94. Relativamente 
ao valor de Q2, este variou entre 0.56 e 0.88, valores um pouco a baixo dos valores 
ideais. Assim, pode-se concluir que este não será um modelo com uma capacidade 
preditiva muito elevada. Relativamente aos modelos PLS, baseados nos espetros NIR 
para estimar a concentração de paracetamol e cafeina, foi possível concluir que a 
capacidade preditiva foi boa com erros quadrados médios (RMSEP) de 12 e 10% para 
o paracetamol e cafeína respetivamente. 
 
Palavras-chave: Produção contínua; Compressão direta; Tecnologia Analítica de 
Processos; Quimiometria; Espetroscopia de Infravermelho Próximo. 
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Chapter 1  
 Motivation    
 
One of the major recent evolution of pharmaceutical drug manufacturing, was the 
effective introduction of the concept of continuous manufacturing. Continuous 
manufacturing allows for faster production, requires greater control and consequently 
higher product quality. It is estimated that the pharmaceutical industry loses about 50 
billion USD a year due to the overall inefficiency of batch production. (1) Continuous 
manufacturing may be a potential solution to assist in solving this problem. Continuous 
manufacturing is not a new concept. In many industries, continuous production, a highly 
automated production concept that integrates multiple production steps, has become 
very common. The benefits that can be obtained, for certain specific processes and 
products, can be very attractive. Continuous manufacturing uses sensor technology and 
in-line analysis to measure the critical physical and chemical properties and processing 
conditions in real time, steering the production process automatically. This allows for an 
uninterrupted flow through multiple production steps from raw materials to the final 
product or dosage form. 
 
The objective is as always, to guarantee that the finished product has uniform 
characteristics throughout the process and meets established quality standards. For 
continuous production to be possible, using all of its potential in the production of a 
pharmaceutical product, it is necessary to have a great knowledge about the entire 
process, as well as everything that is adjacent to it. This work, carried out in the research 
and development continuous tableting line (PROMIS-line), at the School of Pharmacy of 
the University of Eastern Finland, aims to further assist the knowledge increment, 
fundamental for the implementation of a continuous process. The direct compression 
process using a continuous production with process analytical technologies was used. 
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Chapter 2  
 Objectives  
 
The main objectives of this work are: 
 
1. to setup a direct compression method operated under continuous mode fully 
integrated with NIR sensors (mixing stage); 
 
2. to use of the NIR tool to monitor and quantify two active substances 
simultaneously and 
 
3. to resource on NIR spectroscopy for real time process monitoring and product 
quality analysis (key to real time release testing). 
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Chapter 3  
3.1 Introduction 
The pharmaceutical industry is increasingly dynamic, facing several challenges. One is 
to respond in a timely manner to emerging needs, which requires greater flexibility, 
something not always compatible with the more classical methods and processes. Other 
challenges are related to tight cost controls and accelerated development times. All these 
challenges mean that the option of implementing continuous production processes is an 
increasingly more equitable option. Several pharmaceutical companies feel that the time 
has come to invest in this manufacturing mode. In addition, the existing tools for the 
manufacture of pharmaceuticals products allow the existence of high levels of knowledge 
and process control required for continuous production (2). 
In this sense, Dra. Janet Woodcock, director of the Center for Drug Evaluation and 
Research (CDER) at the Food and Drug Administration (FDA), referred to the AAPS 
Annual meeting, October 2011, "At this time, the manufacturing experts of the 1950 
would easily recognize the processes of pharmaceutical production today. Production is 
expected to change over the next 25 years as current manufacturing practices are 
abandoned at the expense of more continuous, flexible and efficient production". 
However, the general pharmaceutical industry is still hesitant to introduce innovation to 
manufacture drugs and drugs products for a variety of reasons. One of the main reasons 
pointed out by industry leaders, lies in regulatory uncertainty, possibly resulting from a 
set of rigid regulations that are unfavorable regarding innovations (3). Recognizing the 
need to eliminate this hesitation, in 2002 the FDA launched a new initiative entitled 
"Pharmaceutical CGMPs for the 21st Century: A Risk-Based Approach." This document 
identifies three main objectives: 
- to encourage the introduction and adoption of new technological advances by 
the pharmaceutical industry; 
- to facilitate the application of modern quality risk management (QRM) 
techniques, including approaches to quality systems for all aspects of production and 
- to encourage approaches that are based on risk. (4) 
It could be argued that this initiative would have been a great impetus for the paradigm 
shift, regarding drugs and drug products production. Increasing production efficiency and 
drug quality with reduced manufacturing costs has become a very appealing appellation 
for a part of the industry. Another thrust with great impact for the new paradigm will be 
the series of guidelines for the manufacture of medicines, namely ICH Q7, Q8, Q9, Q10 
and Q11 and FDA Guidance for Industry - PAT, launched by the International 
Conference on Harmonization (ICH) and the FDA (5). 
Continuous production requires a set of process control systems that serve to mitigate 
the impact of variability, which may occur throughout the entire manufacturing process. 
This set of systems is herein referred to as Process Analytical Technologies (PAT) (6). 
PAT plays a key role in scientific aspects of manufacturing (7). The data that come from 
the use of these tools are later used in multivariate analysis models, which in turn return 
information about the process. These are models, which to a great extent, correspond to 
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tools that contribute to the construction of control mechanisms of the process itself. This 
ensures that any disturbance in the process can be detected and eventually corrected in 
order to achieve that the specifications of the critical quality attributes (CQAs), defined 
for the particular product and framed in the quality target product profile (QTTP) are met 
(8).  
3.2 Continuous manufacturing  
It is possible for drugs and drug products to use a variety of strategies for the 
development of continuous processes. Possible options include (9): 
a. a completely continuous process, in which all the unit operations are sequenced 
to form a single production line; 
b. a completely continuous process as referred to above, but with two or more 
parallel production lines or 
c. a "hybrid" approach with unit operations in continuous and batch mode. 
A continuous process (Figure 1) is characterized by an integration of a set of unitary 
operations, where the starting materials are continuously introduced into the process and 
the products are continuously collected (10). One of the important characteristics of this 
manufacturing mode is the consistency. An ongoing well-designed and an effectively 
executed process can provide a highly consistent product, making its performance 
reliable and at the same time less variable (11). In continuous production, orchestrated 
coordination between different industry partners is essential for successful integration. 
The three key components for successful implementation are the manufacturers of 
analytical equipment tools and processes, active pharmaceutical ingredient (API) 
manufacturers and excipients focused on process controls for consistent deliveries, and 
ease in developing strategies for integrating implementation techniques manufacture of 
the finished product (12). 
Regulators recognize that continuous production is a mode of production with a high 
potential to improve the quality and consistency of drugs and drug products throughout 
the production process, allowing quality to be directly incorporated into the process 
following the efforts of quality by design (QbD). With QbD, product quality is ensured by 
the understanding and control of formulation and manufacturing variables (13). It is thus 
possible to identify sources of variation in product quality as well as to design adequate 
control strategies to work on the identified risk areas (6). This is a "systematic approach 
to development that begins with predefined objectives and emphasizes product 
understanding, process and process control, based on sound science and quality risk 
management" (14). The physicochemical and pharmacological properties of API 
determine the CQAs for pharmaceutical development (13). A strong and complete 
understanding of a product, as well as its manufacturing process, helps to identify the 
CQAs. The use of appropriate statistical methods such as design of experiments and 
risk assessment (RA) as well as PAT and QbD tools can lead to a successful and 
knowledge-based product development (15).  
Regardless of the choice of the manufacturing strategy used by the industry for the 
production of pharmaceuticals, it is necessary to submit and approve any process by the 
regulators. The approval requires the length of a set of regulations. The document for 
submission and approval shall include a general description, which may include a brief 
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outline of each unit operation and its mode of operation, including interfaces between 
unit operations, material flow, proposed flow rate and total operating time of the unit 
process, critical parameters of the process and its ranges, as well as specific information 
for the development and modeling of the continuous process. (9). Regulatory agencies, 
including the FDA, the European Medicines Agency (EMA) and the Japanese Agency 
for Pharmaceutical and Medical Devices (PMDA), support innovation in industries and 
the adoption of continuous production for pharmaceutical production. Generally, there is 
a consensus that continuous production can be effectively implemented within the 
existing regulatory framework, and there are no major regulatory hurdles for 
manufacturers to implement this type of production. However, although the current 
regulatory environment is generally favorable to the adoption of continuous production 
for pharmaceuticals, one of the challenges is a potential gap in standard approaches to 
the regulatory assessment of continuous production processes. Researchers and 
inspectors need to develop more knowledge in technology to determine slightly more 
appropriate regulatory approaches (16). 
 
 
 
 
 
 
 
 
 
Figure 1 - Continuous versus batch (discontinuous) processes (Adapted from (17)) 
 
3.2.1 Quality considerations for CM 
Process development 
Design of experiments (DoE) is defined as "a structured and organized method to 
determine the relationship between factors that affect a process and the outcome of that 
process" (14). Although the DoE is not a substitute for the realization of experiences, it 
is a valuable tool for choosing experiences in an efficient and systematic way for the 
purpose of providing reliable and coherent information (18). This has become a common 
tool to increase processes understanding for interest intervals and can be used for 
comparative experiments, selection experiments, response surface modeling, and 
regression models (6) (19). The understanding of a continuous production process, 
should be established based on the design space and with DoE in the development 
phase. The rapid response of a continuous process to changes in process parameters 
allows a large amount of experimental information to be collected in a short time from 
small quantities of products. Predictive process models can be used as a simulation tool 
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to complement experiences throughout the development of the process and thus 
improve understanding of the process (6). 
For continuous production, understanding the dynamics of how a material flows through 
the process is critical to traceability of the material. This understanding of process 
dynamics can be obtained by characterizing the residence time distribution (RTD) (6). 
RTD is a probability distribution that describes the amount of time that a mass or fluid 
element remains in a unitary operation, throughout a process (6) (20). This (RTD) can 
be easily obtained for all unit operations in a continuous line with a monitoring response 
test performed for each unit operation separately and also for the mechanically 
integrated line. The RTD curve can be used to predict the propagation of material or 
disturbances through the system (6). It is also useful to characterize the axial mixing, to 
predict how fluctuations in a feeder and mixer dissipate and what their impact on the 
uniformity of the mixture and the contents. It can also be used to track materials through 
the process and potentially isolate materials when specifications are not achieved (21). 
The distribution of residence time depends on several factors, such as operating 
conditions, equipment parameters and design, and physicochemical properties of 
materials (22) (6). Thus, knowledge of RTD is a key aspect of a control strategy for 
continuous production processes as it has the ability to adequately isolate and reject 
non-specification materials.  
 
Critical quality attributes 
The quality target product profile (QTPP) provides an description of the quality, safety, 
and efficacy of a specific product for the patient. Moreover, it defines the desired 
characteristics of the product and the goals for its development (15). That way, it should 
be the basis for the development of critical quality attributes (CQAs) and critical process 
parameters (CPPs) as well as a control strategy. CQAs correspond to reference values 
that must be maintained and verified throughout a process. Each CQA incorporates an 
acceptable limit, gap or statistical distribution, serving as a comparison term for the actual 
measurement results (13). CPPs are process parameters whose manipulation has an 
impact on a CQA and therefore should be monitored or controlled to ensure that the 
process produces the desired quality. CPPs are related to the type of equipment, lot size, 
mixing order, mixing time, other operating conditions, etc. (14). Thus, in the design 
space, the physical, chemical or microbiological properties must be defined to ensure 
the consistency of the critical quality attributes of CQA (14) (6).  
In some studies, CQAs are used to describe elements of QTPP (such as dissolution). 
However, there are other studies that consider the CQAs to describe mechanistic factors 
(such as particle size and hardness) that determine product performance. Thus, the 
CQAs are used to describe the two aspects: performance of the product and the 
determinants of your performance (15). An example may be what happens in direct 
compression or simple mixing operations where they are responsible for the segregation 
of the products due to the intense vibrations configured in compression or filling 
machines. Thus, the direct CQAs for these operations will be content uniformity and the 
indirect CQA may be particle size. Alternatively, the uniformity of content may be part of 
the QTPP and the particle size may be included in the CQA (13). 
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For industries such as the pharmaceutical and biotechnology industries, design space is 
very important (23). Process parameters and material attributes are selected for the 
construction of a design space which, when controlled, allows the achievement of a 
consistent quality of the product. These process parameters can be identified by RA and 
process development. The RA identifies product development issues and the risks 
associated with exposure to those problems. The RA process involves risk identification, 
risk analysis, and risk control (13). In this way, it is expected that a product has the 
defined quality if the operation is carried out within the design space.  
 
Process monitoring (PAT) 
PAT are systems that design, analyzes and controls manufacturing processes through 
time measurements, that is, measurements throughout the process, critical raw material 
quality attributes as well as process, in order to ensure the quality of the final product (3). 
In addition to supporting the validation and control of the manufacturing process, the PAT 
tools and principles can be used to gain insight into the process (6). The goal of PAT is 
to improve understanding and control of the manufacturing process. Quality is 
incorporated into pharmaceuticals through a comprehensive understanding of various 
components that make up a whole pharmaceutical product. 
A process is considered well understood when the following conditions are met (3): 
 - All critical sources of variability are identified and explained. The undetected 
variability of the raw materials may manifest itself in the final product if certain critical 
attributes are not well understood or taken into account during a manufacturing process. 
Therefore, a complete identification and understanding of these attributes must be 
performed; (13) 
 - the variability is managed by the process and 
 - product quality attributes can be accurately and reliably predicted within the 
established design space. 
More frequent measurements are required in a continuous process where there is a lack 
of isolated intermediates. Real-time monitoring of process parameters and quality 
attributes of processing materials is an essential component for the establishment of a 
successful control strategy (6). Multivariate models are often used to extract process 
knowledge from data provided by process analyzers. The sampling interface for 
continuous production systems can be challenging as there are some difficulties in 
collecting representative samples of powder samples, which is very prone to errors (6) 
(13). Industrial experience indicates that inefficient measurement performance is often 
attributable to sampling system issues rather than to process analyzer (24). On-line and 
in-line measurements may reduce, but not necessarily eliminate sampling errors (25). 
Thus, considerations with sensor location should be evaluated to obtain representative 
samples and minimize the effect of the probe in the process (6). 
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Control strategy  
In order to ensure the production of a product with a desired and consistent quality, it 
should be noted that a control strategy should be designed. 
A monitoring system is designed to manage planned changes and respond to unplanned 
disturbances. Samples that are analyzed throughout the process should be 
representative and the frequency of sampling should consider the material flow rate at 
system dynamics and the unit dose.   
When developing the product, the influence of the process parameters and the attributes 
of the material on product quality should be studied. Thus, from this information, critical 
process parameters and critical material attributes are identified. It is thus possible to 
maintain control over these parameters so that the quality of the final product is achieved 
(13) (15). In general, a process control system should have three main characteristics 
(26):  
1) fast and controlled startup and shutdown; 
2) complying with all CQAs at the steady state operation and 
3) quality assurance, regardless of disturbances, dynamics, uncertainties, non-
linearity, and constraints. 
A robust control strategy is essential to ensure the consistent quality of the product. 
Certain aspects such as control status, raw materials and intermediates, equipment, 
process monitoring, and sampling should be taken into account for the establishment of 
a control strategy for a continuous process (9). A continuous manufacturing process 
which maintains a control state thus ensures that the quality that is desired is consistently 
achieved. In the initial stages of a process (start-up), as well as at the end of the process, 
(shutdown) sudden changes may occur.  It is therefore important to maintain an 
adequate control state in these situations. It is important, therefore, to ensure that any 
change or change in the process is detected and quickly corrected so that the quality of 
the product is guaranteed. Continuous production may require additional control of raw 
materials. This should happen when multiple batches of a raw material are used in a 
single production batch. Control approaches should be based on product and process 
understanding and may include the use of PAT tools. The quality attributes of raw 
materials and excipients should be tied to the product's CQAs and process needs (9). 
Specifications will be needed as part of the control strategy. Continuous processes may 
include a real-time release testing (RTRT) approach to some quality attributes. RTRT is 
the ability to evaluate and guarantee the quality of the materials in process and / or the 
final product based on process data which typically include a valid combination of 
measured raw material attributes and process controls. This is only achievable because 
the use of PAT tools can be applied to measure substitutes for the quality attributes of 
an end product, some of which have already been incorporated into the control strategy 
for monitoring process control (6). However, RTRT approaches may require an improved 
sampling plan compared to the traditional release test and may involve a larger sample 
size (9).  
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3.2.2 Benefits of CM and challenges for the future 
Continuous production for pharmaceutical industry is an attractive option as processes 
such as compression, roller compaction, and capsule filling are already performed in 
continuous mode (27).  The advantages of continuous production have an impact on 
three areas: (i) product development and quality, (ii) costs, and (iii) footprint. (10) 
Continuous production offers opportunities for improvements such as: 
-an integrated process with fewer separate unit operations with safer, faster, more 
efficient, shorter response times and integrated control and (9) 
- a footprint of smaller equipment (9).  
The production equipment entails fewer expansion problems since the production 
lot size is defined by the "time" factor, so the same size of equipment can be used for 
developmental and pilot studies, clinical trials and complete commercial production (10). 
Since the equipment is smaller, the intermediaries do not need to be stored and 
transferred, so less space is required. In addition, operating expenses decreased as 
operators are not required for processing, transfer and storage (10). 
  - A development approach enhanced by the introduction of QbD, incorporating 
process analytical technology (PAT) (9).  
This type of tools allows the evaluation and assurance of product quality, no 
longer through offline testing, becoming a continuous control. In addition, the production 
of tablets continuously will be more sustainable than through batch production, since the 
footprint significantly reduces. 
- Real-time product quality information and (9) 
- potentially easier to adapt to changing supply needs (9).  
Currently prescribing medicines is based on a one-size-fits-all principle. However, 
more personalized (combination) solutions are needed in several critical areas of 
therapy. Investigations and studies have been followed so that in the near future it is 
possible to prescribe custom medications as recently described in the Precision Medicine 
Initiative (PMI) (28).  The current level of innovation in the designation of dosage forms 
and manufacture of such products cannot meet the needs of personalized medicine. As 
such, new manufacturing solutions are required, which allow the flexible manufacture of 
custom dosages (26). The pharmaceutical industry currently has a limited ability to 
rapidly increase production in response to a possible shortage of drugs or other 
emergencies. Thus the creation of a new facility or manufacturing line in response to 
such emergencies can take up to several months or years, with a batch production; 
however, with a continuous production there can easily be an increase in the volume of 
production without the problems increasing scale, providing greater and better 
responsiveness (6).  
Despite the many advantages that continuous production presents, there are also some 
challenges that need to be addressed (10). Replacing the capital investment made to 
the detriment of a new one for new technologies is perhaps the biggest obstacle to the 
change decision (5). Continuous production has somewhat high starting costs, as well 
as difficult implementation for low volume products (22). In this type of production, 
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materials flow continuously between unitary operations and the product is continuously 
formed over a long period of time. In this way, the process becomes somewhat less 
flexible, since the different unit operations are physically integrated into a specific 
process chain. However recent advances have been made in the development of 
equipment that allows for flexible changes between different operations (10). Unique 
considerations for continuous production should be evaluated when developing a control 
strategy for a continuous process, because the process, product or environmental 
conditions may vary over time. Included in these considerations are, for example, the 
accounting for material attributes that affect fluidity, including the impact of process 
dynamics on quality; initialization and shutdown of processes, and creation of adequate 
measurement systems for process monitoring and control (9) (28).  
A key challenge for research teams in continuous processes is to identify specific product 
groups where continuous production is attractive (11).  
 
3.3 Direct compression 
In tablet production, the most common disadvantages with batch production are 
associated with magnification, lack of real-time quality control, insufficient process 
understanding and long production cycles (29). So, continuous production has great 
potential to overcome some of these problems. For example, the expansion of production 
volumes is achieved with the same equipment through longer process times (29). 
There are different methods of pharmaceutical tablets production. What distinguishes 
them is the dose and physical properties of the mixture, such as compressibility and flow 
(30). Direct compression (DC) is an important process in pharmaceutical technology and 
is one of the methods used for the production of tablets. In the early 1960s, the 
introduction of powdered lactose and Avicel® changed the tableting process and allowed 
a new production process to be used (31). Microcrystalline cellulose (MCC) was 
discovered in 1955 by Battista and Smith being marketed for the first time under the 
Avicel® brand. As early as 1964, FMC Corporation introduced Avicel® PH for the 
pharmaceutical industry as an excipient for direct tablet compression (32) (33). One of 
the difficulties in direct compression and dry granulation is the low content compression. 
Although all cellulose-based polymers are well compactable, there are still particular 
categories of microcrystalline cellulose which have excellent compatibility. With the use 
of these categories it is possible to significantly improve the compressibility of low 
compact powder blends and are therefore widely used as compressibility enhancers in 
the manufacture of tablets by direct compression and dry granulation methods. The 
various categories of MCCs have different fundamental properties, including: 
morphology, particle size, surface area, porosity and density. These properties vary 
according to the type of MCC category, being that categories of smaller particle size 
have good compressibility and poor fluidity, whereas the categories with larger particle 
sizes show little compressibility and excellent flowability (33). Microcrystalline cellulose 
is then widely used in pharmaceuticals, mainly as a binder/diluent in oral tablet 
formulations and capsules. In addition to its use as a binder/diluent, microcrystalline 
cellulose also has some properties of lubricants and disintegrants which make it useful 
in the production of tablets. (32) (34)  
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The current use of the term direct compression is used to define the process by which 
the components are compressed directly from powder mixtures of APIs and suitable 
excipients. No pre-treatment of the powder mixtures is involved by wet or dry granulation 
(30).  DC offers time and economic advantages in the production of a tablet as it is the 
shortest and most direct way, eliminating intermediate stages of granulation and drying, 
in order to obtain the powder for the final dosage form. Today, direct compression plays 
a key role in the pharmaceutical industry, as the continuing trend towards generics 
pushes manufacturers to create production processes as efficient as possible (29) (35). 
Throughout the years, APIs and direct compression excipients have been developed, 
especially diluents and binders. Since these are now commercially available, designing 
direct compression formulations is easily possible (29). It is necessary to take into 
account that in order to obtain a robust and long-lasting dosage form, the functional 
components of the tablets used in the mixture should exhibit good fluidity and 
compressibility, since the use of poorly controlled or inadequately specified raw materials 
can present a number of problems, such as weak fluidity and inconsistent tablet weight, 
unsatisfactory strength, lack of uniformity of content or segregation, and dissolution 
failure. DC is directly affected by the characteristics of the raw materials, since they do 
not undergo any changes in the previous steps in the process (32).  
Although direct compression is an intrinsically continuous technique, simple unit 
operations prior to compression, i.e., weighing and mixing are historically performed in 
batches. To allow direct continuous compression, the integration of continuous powder 
feed units, a continuous dry powder mixer, and a tableting machine is required (36). The 
critical process before compression is mixing. The use of a direct compression process 
presents important challenges related to the uniformity of the product content, as well as 
obtaining and maintaining a homogeneous mixture. Thus, there is a need for a careful 
selection of excipients, powder mixture and process control, so that the out-of-
specification are minimal (29).  
The continuous mixing process requires the evaluation of a large parametric space, 
including: selection of mixing and feeding equipment; evaluation of operational 
parameters such as impeller rotation rate and flow rate; characterization of the effects of 
material properties, such as particle size distribution and powder cohesion, and control 
of environmental variables such as relative humidity and temperature. Many of the 
studies that have been done so far have been in relation to a specific material and in 
relation to the type of mixer. In (22) the focus of this study was to evaluate the flow 
behavior and mixing performance of a continuous-mode powder mixer. It was observed 
that the rotation rate was considered the parameter of the most significant process and 
that most affected the performance of the mixture. Intermediate rotation rates showed 
that the best performance of the blend was largely overpowered by the properties of the 
blend material and the extent of total shear, deformation, applied to the mixer (22).  
Continuous mixing studies were also focused on the influence of process variables on 
the mixing efficiency and flow behavior in mixers (37). Other studies focus on monitoring 
the concentration and homogeneity of the blend after discharging using near infrared 
spectroscopy (NIR). For example, in (38), it was found that the acceptable mixing 
homogeneity, determined by calculating the standard deviation of steady-state drug 
concentration, could be obtained by the continuous process. Other approaches to 
characterize the performance of the mix were focused on the analysis of residence time 
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distribution (RTD) (39). Numerous models are available in the literature to describe the 
mixing and transport of particles through a continuous mixer (36) . The main limitation of 
the use of residence time distribution (RTD) as a predictive tool for mixing performance 
is the inability to capture the micro-blend. This is especially important for pharmaceutical 
blending processes as they combine high product uniformity requirements with small 
sample sizes. In (40), RTD measurements were used to compare the predicted variance 
of the mixer output with the experimental values and the preferred operating conditions 
were determined to facilitate the mixing, and RTD mixing performance indicated better 
mixing performance when the RTD is broader. Other studies suggest that performance 
is driven by the number of revolutions (36).  Still, in (39), the impact of the mixture was 
evaluated, in a continuous process of direct compression, in the CQAs. In general, the 
results highlight that, for the study, continuous mixing within a direct compression 
process is robust and is assessed with a low risk of causing any negative impact on 
pharmaceutical CQAs provided there is adequate control of feeders. 
Continuous powder feeders play a key role in the overall performance of the tablet 
manufacturing line through continuous production. It is crucial to ensure that the feed 
rate of each bulk material is precisely controlled (37). For example, the quality of the 
tablet will vary if there is a great variability in the composition of the inflow, even if the 
mixer and the tableting machine work perfectly (29). The feeder performance defines the 
content of the formulation and is therefore the main unit's operation in continuous 
production. Startup of feeders caused an over-and/or underscoring that should be 
considered when the startup procedure is set. When steady state is reached, feed rates 
remain very constant. The verification of high peaks in feed rate will be largely due to 
accumulation and drop of powder in the feeder exit port (29). Feeders can transfer 
composition problems and flow rate variability to the following unit operations when their 
flow rate variability is not well balanced with the amount of axial mixing within the blender. 
Therefore, the ability to precisely dose a powder over time is a key challenge in the 
overall manufacturing process (36). 
According to (29), the quality of the final tablet can be achieved and will be similar through 
the adoption of a batch or continuous process. However, robust and consistent 
homogeneity can be achieved significantly faster with the continuous process, and thus, 
it is ensured that the batch variation for the batch is minimized. Moreover, with this study 
it is apparent that adaptive control is a fundamental means for robust operation, 
generating consistent quality output. These same observations are also seen in (41), 
where it is shown that continuous mixing and direct compression may offer advantages 
over batch production for tablet manufacture.  
 
3.4 Monitoring  
Monitoring and controlling the composition of a product throughout its manufacturing 
process, in order to achieve the desired quality and robustness, is an important goal to 
be achieved in continuous production. NIR spectroscopy, figure 2, has been widely used 
as a tool for off-line control of raw materials and product quality control (42).  
The American Society of Testing and Materials (ASTM) defines the NIR region of the 
electromagnetic spectrum as the wavelength range of 780-2500 nm corresponding to 
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the range of 12820-3959 cm-1 wave numbers. The most prominent absorption bands 
occurring in the NIR region are related to overtones and fundamental vibration 
combinations of the functional groups C-H, N-H, O-H and -SH. (42)  This method of 
analysis has the advantage of being fast (one minute or less per sample), non-
destructive, non-invasive, almost universal application (any molecule containing CH, NH, 
SH or OH bonds) and a possibility of using intact samples presented directly to the 
instrument without any pretreatment (43). 
A study made by (44), highlighted the feasibility of using NIR spectroscopy also in PAT 
configurations during a pharmaceutical manufacturing process. The continuous mixing 
process can be monitored with NIR spectroscopy, as well as light-induced fluorescence 
(LIF) (10). The option of using NIR spectroscopy is advantageous since NIR spectra can 
be obtained without sample preparation, providing real-time monitoring. Measurements 
performed with NIR can be used to control the feeding speed of the powder feeders and 
the operational parameters of the continuous convective mixers (38). 
Several investigations on the use of NIR spectroscopy in a continuous mixing process 
were developed. PLS-NIR models were constructed to determine the API concentration, 
(38); multipoint systems have been developed (25), to perform the sampling, and the use 
of these has several advantages, such as diagnosis of instrument or process failures. In 
addition, a single spectrometer can be used to monitor an entire continuous production 
process; in (22) the results obtained from this investigation are quite encouraging, 
indicating that the continuous mixer is able to obtain mixtures with a high degree of 
homogeneity. According to this same research, the use of NIR spectroscopy and 
multivariate data analysis is an effective alternative for the real-time determination of API 
at the outlet of the mixer. 
In 2009, the successful use of NIR spectroscopy in a tableting machine to monitor the 
powder segregation was presented at the EMEA / EFPIA QbD Application Workshop 
(45). In an investigation conducted by (46), not only the individual tablets in the tableting 
machine but also the powder stream from a continuous mixer prior to compression were 
monitored. Both calibration and test spectrum data were collected in an in-line form. This 
study demonstrates that it is possible to perform a 100% identity verification, i.e. each 
tablet is monitored individually. The quality of the method was confirmed through tests 
with different API contents, compression speeds and compaction forces. 
NIR spectroscopy combined with multivariate data analysis has become an interesting 
tool in pharmaceutical analysis, both qualitatively and quantitatively (42). Chemometrics 
and multivariate data analysis (MVDA) are the terms used to describe activities related 
to the establishment of the relationship between the complex analytic signal (can be a 
spectrum) and the quality attribute being investigated. MVDA has become a widely 
accepted and widely applied technique in the pharmaceutical industry for qualitative 
purposes (e.g. raw material identification using principal component analysis of portable 
NIR / Raman spectrometers) and quantitative purposes, like measuring the amount of 
water with NIR spectroscopy. The real challenge in implementing MVDA is when data is 
structured in multiple ways (47).  
It is also important to note that continuous quantitative monitoring of pharmaceuticals 
using NIR spectroscopy can be particularly problematic, since the API and excipient 
spectra are themselves complex, and pharmaceutical processes can make the NIR 
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spectrum even more complex (46). However, it is expected that the latest generation of 
NIR instruments will be able to address these problems and further improve the utility of 
NIR spectroscopy for the monitoring of pharmaceutical processes (46).  
 
 
 
 
 
 
 
3.5 Promis-Line: continuous manufacturing line  
This work used to the continuous line (PROMIS-line), at the University of Eastern 
Finland, School of Pharmacy, Kuopio, Finland. PROMIS-line is a modular and flexible 
production line that can be run in three different continuous configurations, depending 
on the type of formulation that is intended to be used. Full line configuration, double 
blending/direct compression configuration, and direct compression configuration, are the 
operating modes of this production line. These are visible in figure 3. The necessary 
equipment, as well as its specifications, for the different configurations are described in 
the table 1.  
 
TABLE 1 - DESCRIPTION OF THE CONTINUOUS LINE 
Equipment Brand and manufacture Specifications 
3 Loss-In-Weight 
powder feeders 
K-Tron, K-ML-D5-KT20 500 – 24000 g/h. 
Loss-In-Weight micro 
feeder 
K-Tron, K-CL-24-KT24 300 – 4000 g/h. 
Loss-In-Weight micro 
feeder 
K-Tron, K-CL-SFS-MT12 32 – 300 g/h. 
Modified Loss-In-Weight 
feeder for lubricant and 
low dose API 
K-Tron, K-cl-24-kt24 
modified 
32 – 150 g/h. 
Two continuous 
blenders 
Hosokawa, Modulomix 300 - 1250 rpm 
 
 
Roller compactor 
 
Hosokawa, Pharmapaktor 
L200/30P, with flake 
crusher FC 200 
Screw speed: 0 - 10 rpm; 
Roll speed: 0 – 20 rpm; 
Roll pressure: 0 – 50 kN; 
Flake crusher: 20 – 100 
rpm 
FIGURE 2 - BASIC NIR SPECTROMETER CONFIGURATIONS. A NIR SPECTROMETER IS GENERALLY COMPOSED OF A LIGHT SOURCE, A 
MONOCHROMATOR (OR INTERFEROMETER IN CASE OF FT TECHNOLOGY), A SAMPLE HOLDER OR A SAMPLE PRESENTATION INTERFACE, AND A 
DETECTOR, ALLOWING FOR TRANSMITTANCE OR REFLECTANCE MEASUREMENTS. (ADAPTED BY (42)) 
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Equipment Brand and manufacture Specifications 
Tableting machine 
PTK, PT – 100 with 
PISCon 
96 000 tablets/h 
Screw conveyer Entecon Spiral Screw Constant speed 
Vacuum conveyer K-Tron,P10-BV-100-VE Constant speed 
Vacuum speed Volkmann, VS200 Eco Constant speed 
 
The continuous manufacturing line allows the use of up to four API feeders and 
excipients for the continuous mixer. Thereafter, the helical conveyor transfers the powder 
mixture to the roller compactor. From the roller compactor, the vacuum conveyor 
transfers the granules to the second feed and mixing station where the LIW granulated 
feeder and LIW microfine feeder (for lubricant) feed the second continuous mixer, this 
step being performed only if necessary. Finally, a vacuum conveyor transfers the 
granules to the tableting machine. 
With the use of the complete production line, the optimum efficiency tested is 20 kg/h. It 
has been found that the upper and lower limits of the line are dependent on the 
formulation (fluidity, cohesion and tackiness of the powder /granules mixture). In addition, 
tableting is the rate limiting equipment on the line. 
The control and monitoring are performed continuously with the use of PAT tools, namely 
NIR probes. Each unit (except the tableting machine) is connected to the control 
computer. The control software was based on Labview using a add-on designed at the 
School of Pharmacy of UEF for this specific purpose. Data are stored in a data server 
(Kuava, Finland). An example of the software running is given in figure 4.  
 
 
 
 
 
FIGURE 3 - SCHEMATIC FIGURE OF FULL LINE CONFIGURATION – 1. TABLETING MACHINE; 2. ROLLER COMPACTOR; 3. POWDER LOSS IN 
WEIGHT FEEDERS; 4. CONTINUOUS MIXER (ADAPTED BY (53)) 
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FIGURE 4 - LABVIEW CONTROL SOFTWARE INTERFACE: MONITORING OF THE POWDER MIXTURE. 1. DURATION OF THE EXPERIMENT; 2. 
SIGNALING OF THE EQUIPMENT BEING USED: FEEDER 1, 4, 5 AND 6; TABLETING MACHINE AND MIXER 2; 3. MASSFLOW CONTROL FOR MCC; 
4. MASSFLOW CONTROL FOR PARACETAMOL; 5. MASSFLOW CONTROL FOR CAFFEINE; 6. MASSFLOW CONTROL FOR MGST 
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Chapter 4 
Materials and methods  
4.1 Pilot continuous manufacturing line 
The continuous manufacturing line setup for this project was composed by a set of 
powder feeders, a continuous mixer and a the tableting machine. Powder feeders and 
mixer are positioned at the top of the tableting machine so that powders flow by the 
action of gravity to the compression machine (Figure 5). Feeding, mixing and 
compression are all integrated into a complete continuous line for tablets production. The 
typical flow rate in this continuous compression line is approximately 20 kg/h. In figure 6, 
it is possible to see a schematic of the configuration of a direct compression line. The 
equipment used to perform the experimental work is listed in table 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 5 - THE DIRECT COMPRESSION CONTINUOUS MANUFACTURING SET-UP USED IN THE EXPERIMENTS. NUMBER 1 LOCATES THE POSITION 
OF THE NIR SPECTROMETER (ADAPTED FROM (41)) 
FIGURE 6 - THE WHOLE CONTINUOUS MANUFACTURING LINE 
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TABLE 2 – CONTINUOUS MANUFACTURING LINE UNIT OPERATIONS  
Tablets Production  Real time monitoring 
(on-line measurements) 
Measuring API 
content/homogeneity (off 
– line measurements) 
Feeders 
one K-Tron, K-ML-D5-
KT20, one K-Tron, K-CL-
24-KT24, one K-Tron, K-
CL-SFS-MT12 and one K-
Tron, K-cl-24-kt24 
modified. 
 
NIR spectrometer 
 
Specim NIR, Spectral 
Imaging Ltd (Oulu, 
Finland) 
UV-Vis Spectrometer 
 
Shimadzu UV-1800  
Continuous Mixer 
Hosokawa, Modulomix 
Tableting Machine 
 PTK PR-1000  
 
4.1.1 Feeders  
Feeders play a key role in a continuous process: the more constant, the more 
homogeneous the output will be. LIW feeders measure the weight loss of material 
discharged from the system. These have an integrated control system that adjusts the 
mass flow based on the amount of material that has been fed, so the material flows from 
the hopper through the feeder to discharge its product at a controlled rate. The load cells 
continuously send weight readings to the controller and the material in the weigh hopper 
is measured as a weight loss / unit time. It compares the calculated weight loss with the 
setpoint and directs the feeder to adjust its rate. Table 3 show all process parameters 
measuring by feeder.   
As soon as the mass flow is equal to the set point, the feeder is considered to be steady 
state. In this study four powder feeders were used (Figure 7): one K-Tron, K-ML-D5-
KT20, one K-Tron, K-CL-24-KT24, one K-Tron, K-CL-SFS-MT12 and one K-Tron, K-cl-
24-kt24 modified.  
TABLE 3 - FEEDER PROCESS PARAMETERS 
 
 
Process parameters  Description  
Set point of raw material [kg/h] Input value 
Mass flow [kg/h] Measured mass flow 
Net weight [kg] The amount of powder in the feeder 
Pert [%] The signal/noise ratio in percentage to 
the set point 
Drive command [%] Percentage in terms of the maximal feed 
rate 
Motor speed [%] Indicates how fast the motors runs 
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4.1.2 Continuous Mixer 
The continuous dry powder mixer consists of a horizontal cylindrical process chamber in 
which a horizontal blade stirrer is rotating. The blades are mounted on a shaft and rotate 
a fixed distance from the process chamber wall. The rotor speed can be adjusted. The 
powder is moved back and forth in the chamber by blades to achieve a more efficient 
mixing process. Although high shear forces can be applied to the blend, the impact 
effects of impact friction will be limited. The mixer has two powder inlets and one outlet. 
In this study, the first entry was used for the excipients and APIs while the second entry 
was used to feed the lubricant. In the present study, the tests were performed with mixing 
speeds of 350 rpm and 1200 rpm. At the center point of the design, 750 rpm were used. 
4.1.3 Tableting machine  
The tableting machine used, figure 8, is an equipment designed in the form of octagon 
thus promoting a saving of space. It is composed of a rigid structure with intelligent 
interior and is fully accessible for easy cleaning and maintenance. In addition, the control 
screen is independent and accessible. 
Control is done through the PISCon system (Figure 8), PTK Pharm Tech Korea. This is 
easy to navigate through its touch screen and using the Windows operating system 
ensures easy and logical operation. It is configured to comply with FDA 21 CFR Part 11 
FIGURE 7 - LIW FEEDERS. 1- FEEDER FOR MGST; 2 - FEEDER FOR PARACETAMOL; 3 – FEEDER FOR MCC; 4 – FEEDER FOR CAFFEINE 
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regulations, which may save relevant production data. Stored production data such as 
batch history or product parameters can be retrieved at any time. Using PISCon in 
conjunction with the Pharmtech Weight Controller (PWR), the press controls the weight 
of the tablet systematically by monitoring the compression force. 
 
 
 
4.1.4 Process monitoring  
 
4.1.4.1 Near infrared spectroscopy  
A NIR-sphere system consisting of a sphere integrated with a tube inside, through which 
the powder flows, surrounded by six fibers placed at different angles was used in this 
work to analyze the mixture. This SPECIM NIR camera offers 320 pixel spatial resolution 
and 50 to 350 Hz image rate. Fibers collect the signals for Specim Spectral Camera. It 
consists of an ImSpector N17E imaging spectrograph, with a temperature-stabilized 
InGaAs detector and a monochrome camera in a wavelength range of 900-1700 nm. 
This system collects 100 spectra per second. The light source is a halogen lamp. 
4.1.4.2 UV-Vis spectroscopy 
To quantify the real amount of paracetamol and caffeine present in the samples collected 
during all the experiments, a UV-VIS spectrophotometer was used. This Shimadzu UV-
1800, figure 9, features a Czerny-Turner mount and has a resolution of 1 nm. 
FIGURE 8 - THE IMAGE ON THE LEFT SIDE CORRESPONDS TO THE COMPRESSION MACHINE, PTK, PT-100. THE IMAGE ON THE RIGHT 
REPRESENTS THE CONTROL SYSTEM OF THE COMPRESSION MACHINE, PISCON SYSTEM. 
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4.2 Raw – materials 
4.2.1 Microcrystalline cellulose (MCC)  
MCC exists in the form of a white, odorless, tasteless, crystalline powder composed of 
porous particles. It is slightly soluble in 5% sodium hydroxide solution and practically 
insoluble in water, dilute acids and in most organic solvents. (34) AVICEL PH 101, FMC, 
Cork, Ireland was the type of MCC used. MCC (cellulose) has, as the pharmaceutical 
formula, (C8H10O5)n, where n is approximately 200. Its molecular weight is 36 000 g/mol. 
(34) In the formulation was used as binder and in an amount of 76.9%. 
4.2.2 Magnesium stearate (MgSt) 
The US Pharmacopoeia describes magnesium stearate as a magnesium compound with 
a mixture of solid organic acids consisting mainly of varying proportions of magnesium 
stearate and magnesium palmitate. It is mainly used as a lubricant in the manufacture of 
capsules and tablets in concentrations between 0.25% and 5.0% w/w. Despite a 
relatively small amount, the lubricants play important roles, they decrease the friction at 
the interface between the surface of a tablet and the die wall during ejection, so that wear 
on the punches and dies is reduced and the tablet is ejected no flaws. (48) Magnesium 
stearate is a very fine powder, white, precipitated or ground, of low apparent density, 
with a slight odor of stearic acid and a characteristic flavor. It provides high lubrication, 
has a high melting point and is chemically stable. (49) It is practically insoluble in ethanol, 
ethanol (95%), ether and water and slightly soluble in hot benzene and hot ethanol 
(95%). (34) Magnesium stearate, with molecular form (Mg(C18H35O2)2) and chemical 
name, octadecanoic acid magnesium salt, has a molecular weight of 591.24 g/mol, and 
was used in an amount of 0.5%. 
4.2.3 Paracetamol 
Paracetamol (N-acetyl-p-aminophenol, acetaminophen), an antipyretic analgesic 
derivative of acetanilide, has long been established as one of the most widely used active 
substances in the world. (50) It is freely soluble in alcohol, in methanol, ethanol, 
dimethylformamide, ethylene dichloride, acetone, ethyl acetate, slightly soluble in ether 
and practically insoluble in petroleum ether, pentane and benzene. (51) Its chemical 
FIGURE 9 - SHIMADZU UV-1800 UV-VIS SPECTROPHOTOMETER 
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formula is C8H9NO2 and has as its molecular weight 151,165 g/mol. Paracetamol was 
used in an amount of 20%. 
4.2.4 Caffeine 
Caffeine (3,7-dihydro-1,3,7-trimethyl-1H-purine-2,6-dione) is an N-methyl alkaloid 
derivative of xanthine that is widely distributed in natural products commonly used in 
beverages. Its consumption has many physiological effects, such as gastric acid 
secretion, diuresis and stimulation of the central nervous system, increasing alertness 
and producing agitation. (50) The caffeine is freely soluble in pyrrole, slightly soluble in 
petroleum ether and freely soluble in tetrahydrofuran containing about 4% water (51). Its 
chemical formula is C8H10N4O2 and has as its molecular weight 194,194 g/mol. This 
active substance, purchase from Sigma – Aldrich® (product of China), was used in the 
formulation in an amount of 2.6%. 
4.2.5 Fumed Silica (FS) 
CAB-O-SIL M-5P (Synthetic Amorphous, Pyrogenic Silica) pyrogenic silica is an 
extremely pure excipient used as a multifunctional additive in the pharmaceutical 
industry. Their addition in a pharmaceutical formulation may be due to material flow 
problems which need to be solved. Thus, the sliding and anti-static properties of 
pyrogenic silica help improve the flow properties of the blend by reducing friction and 
static charges in compression equipment and high-speed capsules. This excipient is also 
compatible with many pharmaceutical ingredients. In addition to these properties, the 
addition of pyrogenic silica to a formulation reduces the segregation between the raw 
materials, promoting uniformity of content. Fumed silica (CAS number 112945-52-5) is 
a powder, white in color and slightly soluble in water (52). 
 
4.3 Formulation and experiments 
In order to evaluate how the performance of direct compression is affected by the 
parameters of the process, a set of experiments were performed (Table 4). The final 
formulation used for the realization of the defined experiences was the result of a set of 
pre-tests. These were carried out with the objective of achieving the best formulation 
possible, with the selected raw materials. Three pre-tests were performed. A first 
formulation was tested, however the tablets obtained had a lower mass than desired, 
thus, for the second pre-test, the type of dies as well as the speed of the mixer were 
altered. With these changes the obtained mass was the desired one, 250 mg, 
nevertheless it was verified the need to modify the amount of paracetamol to a smaller 
value, since the formulation used presented problems of fluidity. Thus, and upon 
completion of the third pre-test, it was found that the formulation used gather the desired 
conditions. The quantities corresponding to each raw material used are described in 
table 5. The achievement of the pretest allowed also set the parameters evaluated and 
varied throughout the experiments. 
A set of experiences was defined considering two factors: mixer speed (750 and 1200 
rpm) and flow rate (5 and 10 kg/h). Additionally, some experiments were defined 
considering a pre-mixture step (mixture of paracetamol (10%) and FS (10%)). These two 
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additional experiments were carried out to verify if the existence of a pre-mixture would 
allow a better flowability of the formulation. 
 
TABLE 4 – SUMMARY FOR THE EXPERIMENTS CARRIED OUT IN THIS WORK. 
 
 
 
 
 
 
 
 
 
 
TABLE 5 – SUMMARY OF THE FORMULATION. 
 
In order to start the set of planned experiments, it was necessary to first introduce the 
excipients and APIs into the feeders. It was cautioned that the amount of raw materials 
was sufficient for each experiment to proceed without interruption in the desired time (at 
least 20 minutes). Whenever a new experience was started it was always verified that 
there was no raw material accumulated in the feeder, "rat-holing". The control of the 
feeders was done through the software Labview. Once the feeders were loaded with the 
starting materials, the second stage of the process was started, the blend. Depending 
on the defined feed rate (5kg/h and 10kg/h), for each experience, it was necessary to 
wait six or three minutes respectively to start the compression phase. The waiting time 
counted from the moment the experiment is started is due to the fact that the tube 
connecting the mixer with the compression machine is almost completely filled with the 
powder. Therefore, when reaching the specified times, the compression phase was 
manually activated. 
 
 
 
 
Experiments Mixer speed    
(rpm) 
Flow rate        
(kg/h) 
Pre-mixture 
1 1200 10 No 
2 750 10 No 
3 350 10 No 
4 1200 5 No 
 5 750 5 No 
 6 1200 10 Yes 
 7 750 10 Yes 
Raw Material Without pre-mixture  
(%) 
With pre-mixture 
 (%) 
MCC 76.9 76.9 
MgSt 0.5 0.5 
Paracetamol 20 10 
Caffeine 2.6 2.6 
FS  not used 10 
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4.4 Paracetamol determination 
The Shimadzu UV-1800 spectrophotometer was used to measure the 243 nm 
absorbance peak characteristic of paracetamol. Given the scarcity of time, it was 
necessary to determine which samples would be analyzed. It was decided to quantify, 
for all experiments, the samples collected at the end of each experiment, that is, samples 
collected at time 20 minutes. A calibration curve for paracetamol was thus constructed, 
figure10. For the construction of the same, several standard solutions of paracetamol 
were used to check the linearity of the measurement (Table 6) in the desired absorbance 
range. Phosphate buffer pH 5,8 was the solvent used for paracetamol standard solutions. 
Tablet samples were weighed, and for experiments 1 and 2, three samples were used, 
obtaining the triplicate UV-Vis results. For the remaining experiments only one tablet per 
sample was weighed. These samples were dissolved in 100 ml of buffer solution, a 
magnetic stirrer was used for mixing the buffer during dilution. 0.75 ml of this solution 
was transferred to 20 ml volumetric flask and completed with water. After dilution, 
samples were taken and put into a syringe having syringe filter on the end of it. Sample 
was filtered through the filter, and the filtered sample was used for measurements. 
 
TABLE 6 - UV-VIS CALIBRATION CURVE MEASUREMENT RESULTS 
Sample ID Type Conc.    
(μg/mL) 
Absorbance 
at 243nm 
P1 Standard 5 0.332 
P2 Standard 10 0.644 
P3 Standard 15 0.962 
P4 Standard 20 1.292 
P5 Standard 25 1.605 
P6 Standard 30 1.931 
 
FIGURE 10 - CALIBRATION CURVE FOR THE PARACETAMOL UV-VIS DETERMINATION METHOD. 
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4.5  Data processing and analysis 
 
4.5.1 Spectral acquisition and processing  
A NIR spectrometer connected to the in-line integration sphere, coupled to the output of 
the continuous mixer, allowed the collection of NIR data for each experiment. These data 
were processed and stored by the proprietary acquisition software. The spectra were 
processed with Matlab (The MathWorks Inc. Natick, MA). Spectra were pre-processed 
with the Savitzky-Golay (first derivative and 15 points).  
4.5.2 Multivariate models  
Two PLS models were constructed, the first one was constructed with the purpose of 
analyzing the influence of the process variables on specific parameters. The first model 
was built with the purpose of paracetamol and caffeine prediction from NIR spectra. The 
spectra were pre-processed with Savitzky-Golay algorithm (SavGol) along with the first 
derivative (first order, 15 points). Before the construction of the PLS models, from NIR 
spectra, all datasets were submitted to mean-centring. The number of latent variables 
was optimized with cross validation. The model error is given as the mean quadratic error 
of prediction (RMSEP) and is relative to the prediction set. The second PLS model was 
built using Modde (Version 12.1, Umetrics, Sweden). This model related the process 
variables with the process responses. The selected factors were: mixer velocity, flow rate 
and premixing. The evaluated responses are related to the physical properties of the 
tablets, such as: mass, hardness and thickness. The model's prediction ability was 
evaluated by analysis of variance (ANOVA).   
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Chapter 5  
Results and discussion  
5.1 Process analysis 
In this section we will analyze the unit operations of the direct compression process. The 
discussion is divided in the analysis of the feeders, mixer and tableting operations. 
5.1.1 Feeders 
The first stage of the whole process consists in placing the raw materials in the respective 
feeders. It is possible, through the previously mentioned program, to monitor and acquire 
data on the feed rate of each feeder over time. The data obtained, for each used feeder, 
correspond to the parameters that are in table 3, measured all over the experience time.  
It is fundamental, for the direct compression process, to ensure that the feed rate is 
maintained and performed within the defined parameters. Thus, the following analysis 
concerns the evaluation of this phase of the process. All experiences were analyzed. 
However, since the results obtained are very similar to each other, only the procedure 
for experiments 5 and 6 will be demonstrated. Figure 11 relates to two graphs 
constructed with the different mass flows over time for each of the feeders used, for the 
experience 5 and 6, respectively. By comparing the obtained results with the values 
defined for each quantity of raw material, it is possible to conclude that the variations that 
exist in relation to the established value are small, and in this way the steady state will 
be reached. However, since for the process in question several feeders were used, the 
multivariate methods offer much more robust tools to evaluate the steady state of the 
feeders used. 
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Thus, using the feeder process data, one model, for each experiment, is constructed 
using principal component analysis (PCA). Table 3 shows the process parameters and 
those that are included in the model (except the set point, which is a controlled input 
variable). Thus, the time evolution of the process is visible in the PCA model. The model 
was constructed using SIMCA and the values of Q and R, for each experience, are in 
table 7. This is the final model, in which parameters were extracted, pert, drive command 
and motor speed from the MCC and MgSt feeder. These parameters were excluded 
based on their meaningfulness, which was much lower than the other parameters, 
include in the model. From the scores plot, figure 12, the evolution of the feeder scores 
is clearly observed. For Experiment 5 (Figure 12, upper image), observations begin in 
the lower left corner. In Experiment 6 (Figure 12, bottom image), observations begin in 
the lower right corner and progress to the upper right corner. The instant of time when 
the observations enter the ellipse is approximately 0.9 minutes, for experiment 5 and 
approximately 0.73 minutes for experiment 6. The mass flow for caffeine and 
paracetamol was checked. For experience 5, the value of paracetamol (1,067 kg/h), and 
caffeine (0.086 kg/h), are not within the specifications of label claim i.e. between 105% 
and 95%. Thus, in this way, it is not possible to conclude that the observations that lie 
within the ellipse are in steady state. Concerning experience 6, the observed values of 
paracetamol (2.17 kg/h) and caffeine (0.26 kg/h) are within the specifications of label 
FIGURE 11 - VARIATION OF MASS FLOW FOR ALL USED FEEDERS – RUN 5 ON TOP AND RUN 6 ON BELOW. 
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claim i.e. between 105% and 95. Thus it can be said that from the moment in which the 
observations enter into the ellipse, the process enters steady state. It should be noted 
that, for the mixture to be the best possible, all feeders must operate at steady state. 
When steady state is reached, feed rates remain very constant. Random spikes in feed 
rates, such as those occurring at some points in figure 11, are due to the accumulation 
and drop of powder in the feeder exit port. 
 
 
 
TABLE 7 – SUMMARY OF PCAS MODELS. 
 
 
 
 
 
 
 
Experiment 
Principal 
component 
R2X R2X(cum) Q2X Q2X(cum) 
# 5 
1 0.25 0.25 0.0597 0.0597 
2 0.184 0.434 0.045 0.102 
3 0.171 0.606 0.203 0.284 
4 0.105 0.711 0.088 0.347 
# 6 
1 0.292 0.292 0.155 0.155 
2 0.17 0.463 0.0604 0.206 
3 0.163 0.626 0.153 0.328 
4 0.112 0.738 0.11 0.402 
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Figure 13, refer also to data obtained from the feeders, and with this second analysis, 
the objective is to analyze only the amount of paracetamol and caffeine, and see if they 
remain constant throughout the feeding phase around the set point. Analyzing each 
experience, it is apparent that the amount of paracetamol in the experience 1,2 and 3 is 
relatively controlled over time, since it is very close to 20% (set point). Experiments 6 
and 7 were the ones that showed the best performance, because the variations around 
the set point were minimal throughout the process. Regarding the variation of the amount 
of caffeine throughout the experiments, it is possible to visualize that there is a difficulty 
in keeping the quantity defined and controlled, being in agreement with the previous 
analysis, in which it was not possible to verify the steady state of the caffeine feeder in 
all experiments. 
 
FIGURE 12 - SCORES PLOT FROM PCA MODEL CALIBRATED WITH FEEDER PARAMETERS, FROM EXPERIMENT 5, UPPER IMAGE, AND 
EXPERIMENT 6, BOTTOM IMAGE. 
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 In the experiments carried out at a rate of 5 kg/h, experiment 4 and 5, there was an even 
greater difficulty in maintaining the values of paracetamol and caffeine at the defined 
value, indicating that this feed rate, for the formulation in question, does not will be the 
most indicated.  
  
 
 
 
FIGURE 13 - FEEDER DATA: VARIATION OF PARACETAMOL AND CAFFEINE CONCENTRATIONS 
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5.1.2 Continuous mixer 
The following analysis was based on data collected by the NIR spectrometer connected 
to an in-line integration ball which was coupled to the output of the continuous mixer. 
The processing of these data began with the spectra processing. Each consecutive 100 
spectra were averaged to give spectrum per second. Due to the fact that there is a region 
of this spectrum that would not have relevant information for the study, wavelength below 
950nm were not considered. It was observed that the result of the exploratory analysis 
was similar for all experiments. For illustrative purposes only the results for experiment 
#2 will be analyzed here. NIR spectra noise can be mitigated by averaging consecutive 
spectra (the frequency of spectra acquisition was 100 per second). Noise can also be 
reduced using some pre-treatment methods.  Figure 14 shows raw and after application 
of Savitzky-Golay with first derivative. 
 
FIGURE 14 - RAW NIR, (UPPER IMAGE) AND PRE-PROCESSED (SAVGOL + 1ª DERIVATE) NIR SPECTRA (BOTTOM IMAGE) OBTAINED FOR 
RUN 2. 
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When performed on an entire sample, the first derivative effectively removes baseline 
and emphasizes the lower frequency signals. After applying the pre-treatment to the 
spectrum, as well as mean-centring, a PCA model was developed. Model was developed 
with the objective of analyzing the internal structure of the data. This model was 
constructed with two latent variables. In this way, the score plot of the experiment number 
2 can be seen in figure 15. The first main component (PC1) captures 97% of variance, 
and the second main component (PC2) captures 2.2% of variance. The scores are 
colored according to the Hotelling's T2 statistic. Thus, the samples that are inside the 
ellipse are those closer to the center of the model, as it is the case of the group that 
presents the color yellow and green, corresponding this to the steady state. The 
observations one to eighteen were excluded because they were considered outliers. 
Figure 15 identifies a clear trajectory of the process. The process starts in the upper left 
corner, outside the ellipse. Following the scores along the PC1 axis, we see the 
approximation of these to the center of the ellipse, and at the end of the process, the 
final scores are outside the ellipse, in the third quadrant. 
In figure 16, the Hotelling's T2 statistic is shown as a function of the squared residuals 
statistic or distance to model statistic (Q). The Q statistic measures the distance between 
each sample and the model. The lines that are visible in the figure refer to the 95% 
confidence limits. 
 
 
 
 
 
FIGURE 15 - THE SCORE PLOT FROM PCA MODEL CONSTRUCTED WITH NIR DATA FOR RUN 2 
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The first component was also represented as a function of time (Figure 17). It is clear 
that there is variability over time. This variability must be further analyzed. It may be 
related with fluctuations in terms of product characteristics or/and caused by an 
inefficient procedure to capture the NIR spectra. The observed changes seem to have 
some autocorrelation which might indicate indeed some variability in the processed 
product. 
 
The analysis of the PCA scores, figure 18, revealed variations that would not be 
expected, in this way, possible causes were explored. At first, it was thought that these 
changes were due to variations caused by fluctuations in the feeder mass flows. 
Consequently, an analysis was made of the periodicity of the mass flows in the feeders 
as well as to the periodicity of the scores for all experiences. The obtained results, 
comparing the periods in which the variations occur in the scores, with the same periods 
in the mass flows of raw materials, show that there is no relation or reason for these 
ranges of variations in the experiences to occur. Moreover, in the analysis done to the 
FIGURE 16 - HOTELLING T2 VS Q RESIDUALS FROM PCA MODEL (RUN 2) 
FIGURE 17 - PC1 REPRESENTED IN FUNCTION OF TIME (RUN2) 
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feeders, it is concluded that these, for most raw materials, have managed to reach the 
steady state, maintaining the mass flow around the defined set point. Therefore, these 
variations should not be due to problems related to fluctuations in the mass flow of the 
feeders. We then attempted to understand which functional groups were contributing to 
the ranges of variations that occurred. For this the wavelength contributions to the scores 
were analyzed. It was first necessary, for each experiment, to define the intervals of the 
variations, and thus to analyze individually each of them. With the intervals defined, the 
analysis of the contributions can take place. Contributions for the first and second 
components (Figure 19) were analyzed.  During the analysis, we recorded the 
wavelengths that contributed most significantly to the variations that occurred in each 
defined interval. Thus, it was found that the wavelengths, which most significantly 
contributed to the variations, both using the first component and the second component, 
were the same, 1313 - 1471 nm and 1577 - 1603 nm. After discovering that these were 
the wavelengths that were contributing to the variations, it was found which functional 
groups would absorb at these intervals. It was found that CH3, CONHR and OH could 
affect the NIR signal. These are functional groups that belong mainly to paracetamol, 
which leads us to conclude that these variations could be due to changes in the quantity 
of this raw material, when the mixture is analyzed by NIR. As already mentioned, within 
the NIR measuring sphere, there is a glass tube, and since paracetamol is very sticky, it 
may contribute to the small clusters of the paracetamol-containing mixture adhering to 
the tube, in a random way, provoking the variations that are observed in the scores. 
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FIGURE 18 - REPRESENTATION OF PC1 OVER TIME FOR ALL EXPERIMENTS (EACH MODEL WAS CALIBRATED WITH DATA FROM DIFFERENT 
EXPERIMENTS). 
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5.1.2.1 Paracetamol and caffeine prediction by NIR spectroscopy 
A new set of experiments, called calibration experiments, were performed to assist in the 
development of a methodology to estimate paracetamol and caffeine from the NIR 
spectra collected at the outlet of the mixer. The new experiments are described in table 
8. The first three experiments were set varying only the paracetamol content: 80, 95 and 
105%. In the following three experiments, the values of caffeine (80, 105 and 120%) 
were changes keeping the remaining percentages constant. These experiments were 
conducted at a flow rate of 10 kg/h. Spectra obtained from these experiments were used 
to calibrate 6 different PCA models. Spectra was processed with the pre-treatments 
explained above. The mean spectra collected for each experiment was used as the X-
block and the corresponding % of caffeine and paracetamol were the Y-block for PLS 
FIGURE 19 - WAVELENGTH CONTRIBUTIONS FOR THE FIRST AND SECOND SCORES (RUN2) 
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models. Therefore, two PLS models were calibrated (one for paracetamol and one for 
caffeine). 
TABLE 8 – EXPERIMENTS FOR PLS MODELS CONSTRUCTION  
 
Paracetamol                      
(kg/h) 
Caffeine          
(kg/h) 
MCC                    
(kg/h) 
MgSt                             
(kg/h) 
% of
API 
 
Calibration 1 
(80%API) 
1.6 0.26 8.09 0.05 16 Change in 
paracetamol 
percentage 
in 
formulation 
Calibration 2 
(95%API) 
1.9 0.26 7.79 0.05 19 
Calibration 3 
(105%API) 
2.1 0.26 7.59 0.05 21 
Calibration 4 
(80%API) 
2 0.208 7.742 0.05 2.08 Change in 
caffeine 
percentage 
in 
formulation 
Calibration 5 
(105%API) 
2 0.273 7.677 0.05 2.73 
Calibration 6 
(120%API) 
2 0.312 7.638 0.05 3.12 
 
A model with a latent variable was the best model obtained, both for predicting 
paracetamol and for caffeine. The performance of both models was evaluated by internal 
and external validation. The internal validation of the model provides an estimate of the 
predictive performance of the model, which can be evaluated by the RMSECV (cross-
validation error) and the coefficient of determination for cross-validation (R2cv). In 
external validation, the calibration model was tested using data that was not used to 
construct the model. This method provides a reasonable assessment of the predictive 
performance of the model with new samples. The external validation is evaluated by the 
RMSEP and the determination coefficient for Prediction (R2p). Therefore, 6 experiences 
were used to construct the two models. In the case of the predictive model of 
paracetamol, the three experiments were used in which the value of caffeine was altered 
to predict paracetamol and the opposite occurred for the caffeine prediction model. 
Figure 20 and 21 show the estimation performance of the model for paracetamol and 
caffeine, respectively. The RMSECV values for both the predictive model of paracetamol 
(0.22%) and the predictive model of caffeine (0.10%) are low, being a good indication for 
the predictive capacity of the model. 
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Figures 22 and 23 refer to the results of the test performed on the calibration model, 
using the experiments that were not used to construct the model: caffeine data (three 
last experiments) to predict paracetamol and paracetamol data to predict caffeine (three 
first experiments). The values obtained from RMSEP for paracetamol (12%) and for 
caffeine (10%) were also low. Thus, it can be concluded that the models will have a good 
prediction capacity. These two models were constructed only with six calibration 
experiences, so they lack robustness. Therefore, it would be necessary an additional set 
of experiments for calibration to add robustness to the PLS models. Nevertheless, data 
for all seven CM experiments were applied to these models (Figure 24).  
FIGURE 20 – MODEL PREDICTION FOR PARACETAMOL 
FIGURE 21 – MODEL PREDICTION FOR CAFFEINE 
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FIGURE 22 – TEST PERFORMED TO THE CALIBRATION MODEL FOR PARACETAMOL 
FIGURE 23 – TEST PERFORMED TO THE CALIBRATION MODEL FOR CAFFEINE 
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These results show that the predictions for paracetamol and caffeine aren´t completely 
coincident with the expected values. The value that should be achieved, for all 
experiences, should be 20% for paracetamol and for caffeine, 2.6%. As can be seen in 
figure 24, there are some mismatches relative to the expected values. It is also important 
to note that in the case of caffeine, the difference between the expected and the verified 
values is more frequent and the oscillations more pronounced. 
 
 
FIGURE 24 – OBTAINED RESULTS FOR ALL EXPERIMENTS FOR PREDICTIONS OF PARACETAMOL AND CAFFEINE, OBTAINED WITH PLS MODELS: 
PLS MODEL FOR PARACETAMOL AND PLS MODEL FOR CAFFEINE.  
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5.1.3 Tableting 
During the course of all experiments, samples of tablets were collected. These were 
collected during 20 minutes with a 2 minutes interval. Collected tablets were analyzed 
according to the mass, hardness, and thickness. For each set of samples, 20 tablets 
were randomly selected, as defined by the European Pharmacopoeia (EP 6.0). The 
procedure adopted for the analysis of the three properties previously mentioned was the 
same (Figure 25). For each experiment, samples were collected at 10 sampling periods. 
Twenty tablets were selected from each of these 10 sampling periods. Averages were 
calculated for each property (see Annex 1). The final value, for each property and 
experiment, resulted from the average of all 10 sampling periods. The final values are 
shown in table 9.  
 
TABLE 9 - MEASUREMENTS OF PHYSICAL PROPERTIES FOR TABLETS SAMPLES 
Experiments Average weight 
(mg) 
Average hardness 
(N) 
Average 
thickness 
(mm) 
 1 300.23 142.31 2.99 
 2 283.18 134.59 2.93 
 3 278.07 152.32 2.93 
 4 332.03 173.26 3.14 
 5 300.89 154.19 2.99 
 6 291.32 213.10 2.97 
 7 289.75 226.56 2.95 
Mean  291.32 226.56 2.96 
 Standard 
deviation 
16.41 33.04 0.06 
CV (%) 5,63 14,59 2,26 
 
The first property to be analyzed was the uniformity of mass. According to the European 
pharmacopoeia (EP 6.0) and taking into account that the average obtained for all 
FIGURE 25 - SAMPLING PROCEDURE FOR ALL EXPERIMENTS 
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samples was always higher than 250 mg, the permitted deviation is 5% (no more than 
two units outside the specified limits) and none can be outside the 10% limit. By analyzing 
all sets of samples, it is concluded that in some experiments the specifications mentioned 
above are not fulfilled, mostly due to the fact that they exceeded the 5% limit. 
The variation of the results of the final averages, relative to the mass of the tablets, 
obtained for each experiment, are shown in figure 26. In addition, the confidence limits, 
for the mass are also represented in figure 26. The error bars were calculated taking into 
account the percentage defined in the EP (+/- 5%). Experiment 4 is, therefore, outside 
the defined limits. It is to be noted that a higher speed of the mixer resulted in higher 
tablet weights due to better flow properties, thereby improving matrix filling.  
 
 
Hardness was the second property analyzed. Figure 27 concerns the variation of this 
property throughout the experiences. The error bars were calculated taking into account 
the standard error. It should be noted that the values obtained are quite high, and 
inconstant. The standard deviation and consequently the coefficient of variation are high 
(Table 8). Despite there is no specification in the EP for hardness, the observed 
differences may interfere with the disintegration time and dissolution profile 
FIGURE 27 -  MEAN VALUES OF HARDNESS FOR EACH EXPERIMENT 
FIGURE 26 - MEAN VALUES OF MASS FOR EACH EXPERIMENT 
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Finally, the last physical property analyzed was the thickness (Figure 28). The error bars 
were calculated taking into account the standard deviation. The thickness of a tablet is 
determined by the diameter of the matrix, the amount of material filling it, the compaction 
characteristics and the force applied during compression. Thus, as all the features 
referred to above were held constant throughout the experiments the thickness values 
are very close to each other.  
 
5.1.3.1 Tablets monitoring 
The aim of the following analysis is to compare the results obtained with the UV-Vis 
based measurements with the results obtained with feeder data, for the samples selected 
(samples collected at 20 min). For the UV-Vis measurements, as caffeine is also active 
at the selected wavelength for paracetamol, its presence will cause the results obtained 
with the UV-Vis method to indicate concentrations of paracetamol higher than the real 
concentrations. Since the standard is made with pure paracetamol and the sample 
having some caffeine, the baseline increases slightly. For exceed this problem and once 
the amount of caffeine is much lower than the amount of paracetamol and having this 
value always constant in the experiments (2.6% of caffeine in all experiments), a 
normalization (auto-scaling) was performed to the values obtained so that the 
interference of the caffeine could be mitigated. Thus, it becomes possible to perform a 
comparison in terms of variance of the normalized values of the UV-Vis results with the 
normalized values obtained from the feeder.  Figure 29 compares the autoscaled values 
of the concentration of paracetamol determined by the UV-Vis method and the theoretical 
values of concentration estimated from the paracetamol feeder data. Results show that 
although there are some experiments with similar values, there's not a strong correlation 
when considering all experiments. 
 
FIGURE 28 - MEAN VALUES OF THICKNESS FOR EACH EXPERIMENT 
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5.1.3.2 Tableting process modeling   
This model was constructed with the objective of evaluating the influence of the changed 
variables in the defined response parameters for tablets. Table 10 shows the factors and 
the responses to be evaluated. Thus, the variables included were: mixer velocity, mass 
flow, and whether or not the pre-mixture was performed. The evaluated responses were: 
weight, hardness and thickness. Linear models were calibrated without interactions for 
the three parameters studied.  
 
TABLE 10 - EXPERIMENTAL DESIGN TABLE. 
   
Input values Evaluated responses 
Exp No Exp 
Name 
Incl/Ex
cl 
Mixer 
speed 
(rpm) 
Flow 
rate 
(kg/h) 
Pre-
mixtur
e 
Weight 
(mg) 
Hardne
ss 
(N) 
Thickn
ess 
(mm) 
1 N1 Incl 1200 10 without 300.23 142.31 2.99 
2 N2 Incl 750 10 without 283.18 134.59 2.93 
3 N3 Incl 350 10 without 278.07 152.32 2.93 
4 N4 Incl 1200 5 without 332.03 173.26 3.14 
5 N5 Incl 750 5 without 300.89 154.19 2.99 
6 N6 Incl 1200 10 with 291.32 213.1 2.97 
7 N7 Incl 750 10 with 289.75 226.56 2.95 
 
Figure 30 displays the scaled regression coefficients with confidence intervals. By 
default, the coefficient graph shows coefficients for scaled and centralized variables. 
Scaling the data makes the coefficients comparable. The coefficient is significant 
FIGURE 29 - COMPARISON BETWEEN THE VALUE MEASURED BY THE FEEDER WITH THE UV-VIS MEASUREMENT, FOR SAMPLES TAKEN AT TIME 
20 MIN. 
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(different from noise) when the confidence interval does not include the zero. For the 
models presented here, the non-significant terms were removed. In this way it can be 
concluded that the most significant variable that most influences hardness is whether or 
not we carry out a pre-mixture. It is still perceptible that for the weight, this will be 
influenced positively by the speed of the mixer, i.e., higher speeds of the mixer will 
correspond to tablets having a higher mass. For weight it is also visible that this response 
is affected negatively by the flow rate, that is, for high flow rate, the weight will be lower. 
 
 
 
Figure 31 show the summary statistics for each response with two parameters: R2 and 
Q2. R2 is the percentage of the response variation explained by the model, R2 being an 
adjustment measure, allows to determine how well the model fits the data. Thus, a large 
R2 value is a necessary condition for a good model, but it is not sufficient. For each of 
the responses, weight, hardness and thickness, correspond respectively, 0.86, 0.94, and 
0.78 values of R2. Q2 this is the percentage of response variation predicted by the model 
according to the cross validation. Q2 tells you how the model predicts new data. A useful 
model should have a large Q2. The values obtained for the defined responses were, 0.75, 
0.88 and 0.56, respectively.  Another important parameter in the model analysis is the p-
value for the regression. The p-value should ideally be less than 0.05. All models 
accomplish this criterion. 
 
 
 
FIGURE 30 - COEFFICIENTS FOR THE THREE ESTIMATED MODELS. 
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Models’ prediction (Figure 32) shows the observed versus predicted response values. 
For the three models, the points are relatively close to the diagonal, which is a good 
indication of the model. The values of Q2 for weight, hardness and thickness are 0.75, 
0.88 and 0.56, respectively. 
 
 
From the loadings (Figure 33) it can be seen that the mass is positively affected by the 
speed of the mixer and negatively by the flow rate. It is further appreciated that the 
thickness is also positively affected by the speed of the mixer and negatively by the flow 
rate. 
 
 
FIGURE 31 - R2 AND Q2 FOR WEIGHT, HARDNESS AND THICKNESS MODELS. 
FIGURE 32 - MODELS´ PREDICTION FOR WEIGHT, HARDNESS AND THICKNESS 
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The normal probability plot of residuals shows the standardized residuals on a double 
log scale (Figure 34). The residuals represent the non-modeled part of the model. Thus, 
it is possible to detect outliers and evaluate the normality of the residuals. These should 
be normally distributed, and for this, they should be in a diagonal straight-line. 
 
 
  
 
 
 
 
FIGURE 33 - LOADINGS FOR WEIGHT, HARDNESS AND THICKNESS. PLS MODELS 
FIGURE 34 - RESIDUALS FOR WEIGHT, HARDNESS AND THICKNESS 
Multivariate analysis of a direct compression pharmaceutical tablets continuous manufacturing process. 
 
 
51 
Chapter 6  
 Conclusions  
 
In this work a set of experiments was designed with the purpose of evaluating a 
continuous manufacturing direct compression process for tablets production, involving 
the unit operations feeding, mixing and tableting. Factors like the mixer, feeding flow rate 
and existence of premixture were evaluated. The experiments responses included 
tablets physical properties, such as weight, hardness and thickness. The process was 
additionally monitored by near-infrared spectroscopy with a probe located immediately 
after the mixer's outlet port. 
 
The results obtained from the NIR measurements revealed problems with the NIR probe 
(encompassing glass wall tube trough which powders flow). Given that paracetamol is a 
very tacky feedstock, it sometimes accumulated on the walls of the whole glass, 
releasing it thereafter, thereby causing NIR spectra to have somewhat periodic 
fluctuations, corresponding to accumulation periods. This problem reinforces the idea 
that, despite the pre-tests performed for formulation selection, the selected formulation 
was not the most favorable for this specific probe. Additionally, the geometry of the probe 
and location should be re-evaluated. 
 
Relative to the control of the feed rate, a fundamental element in a direct compression, 
it was visible that this first step of the process was carried out without great variations in 
relation to the set points defined for each raw material. Thus, the data analyzed, in 
relation to the feed rate of caffeine and paracetamol, made it possible to predict that their 
concentrations in the tablets would be as expected. During the experiments, it was still 
possible to see that the experiences with a feed rate of 5 kg/h had very poor fluidity. 
 
According to the PLS models constructed to evaluate the influence of the factors on the 
selected responses, the mass of each tablet is positively affected by the mixer speed 
and negatively affected by the flow rate. In addition, this model predicts that the hardness 
is affected by the existence of a premixture step as experiments with premixture include 
an additional component (fumed silica). For the three models, the R2 varied between 
0.73 and 0.94. Regarding the values of Q2, they varied between 0.56 and 0.71, 
somewhat low values. Thus, it can be concluded that models don't have a very high 
predictive capacity. 
 
Regarding the PLS models correlating NIR spectra with content of paracetamol and 
caffeine in the powder mix at the outlet of the mixer, in both cases the models obtained 
showed good predictability. The RMSEP values for the predictive model for paracetamol 
(approx. 12%) and caffeine (approx. 10%) are low, being a good indication for the 
predictive capacity of the model. 
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Future Perspectives  
 
During the experiments a recurrent problem was found, related to the accumulation of 
powder in the outlet chute of the tablets, causing a need to frequently it was necessary 
stop the process for a few seconds. This problem is due to the poor flowability of the 
formulation, a problem mainly caused by paracetamol. A possible solution would be to 
adjust the excipients to solve this problem. 
 
The flow rate was only changed between the values of 5kg/h and 10kg/h and it was 
noticeable that during the experiments at a rate of 5kg/h the fluidity problem of the 
formulation stood out. However, at a rate of 10kg/h this problem was practically non-
existent. It would be interesting to increase the range of values between 5 kg/h and 10 
kg/h for the flow rate in the experimental design. 
 
It would be important for monitoring and control, to use a NIR probe at the outlet of the 
tableting machine so that tablets could be analyzed. 
 
The UV-Vis method for quantification of paracetamol could be improved so that both 
caffeine and paracetamol could be simultaneously estimated (using the entire UV-Vis 
spectrum and a multivariate calibration) therefore allowing a best estimate of the 
compounds. 
 
In the experimental design, it would be interesting to change variables related with the 
compression stage. 
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Annex 
Annex 1 - Analyzed physical properties: Weight, Thickness and Hardness. Run1, Run2, Run3, 
Run4, Run5, Run6, Run7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 2 4 6 8 10 12 14 16 18 20
Average Weight 300 296 293 264 304 304 303 312 309 307 311
(+5%) 315 315 315 315 315 315 315 315 315 315 315 315 315 315 315 315 315 315 315 315
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0 2 4 6 8 10 12 14 16 18 20
Average Weight 256 268 271 287 281 279 282 284 282 287 281
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(+0,5%) 349 349 349 349 349 349 349 349 349 349 349 349 349 349 349 349 349 349 349 349
(-0,5%) 315 315 315 315 315 315 315 315 315 315 315 315 315 315 315 315 315 315 315 315
300
310
320
330
340
350
360
370
W
e
ig
h
t 
(m
g
)
Time (min.)
Average weight 
Average Weight
(+0,5%)
(-0,5%)
 
0 2 4 6 10 12 14 16 18 20
Average Thickness 3,217 3,2025 3,241 3,293 3,162 3,103 3,062 3,043 3,153 3,041 3,041
2,9
2,95
3
3,05
3,1
3,15
3,2
3,25
3,3
3,35
Th
ic
kn
es
s 
(m
m
)
Time (min.)
Average Thickness
 
0 2 4 6 8 10 12 14 16 18 20
Average Hardness 203,8 194,8 191,25 211,15 189,25 173,35 136,7 146,95 179,2 140,8 138,65
50
70
90
110
130
150
170
190
210
230
H
a
rd
n
es
s 
(N
)
Time (min.)
Average Hardness
Multivariate analysis of a direct compression pharmaceutical tablets continuous manufacturing process. 
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0 2 4 6 8 10 12 14 16 18 20
Average Weight 295310 298 299 298 302295 305 293 305307
(+5% 316316 316 316 316 316316 316 316 316316 316 316 316 316316 316 316 316316
(-5%) 286286 286 286 286 286286 286 286 286286 286 286 286 286286 286 286 286286
270,00
275,00
280,00
285,00
290,00
295,00
300,00
305,00
310,00
315,00
320,00
W
e
ig
h
t 
(m
g
)
Time (min.)
Average weight 
Average Weight
(+5%
(-5%)
 
0 2 4 6 8 10 12 14 16 18 20
Average Thickness 2,977 3,010 2,987 2,993 2,989 3,001 2,984 3,010 2,971 3,005 3,007
2,950
2,960
2,970
2,980
2,990
3,000
3,010
3,020
Th
ic
kn
es
s 
(m
m
)
Time (min.)
Average Thickness
 
0 2 4 6 8 10 12 14 16 18 20
Average Hardness 147,4 174 145,6 152,3 150,7 158,6 140,6 164 134,2 163,7 165,1
100
110
120
130
140
150
160
170
180
H
ar
dn
es
s 
(N
)
Time (min.)
Average Hardness
 
0 2 4 6 8 10 12 14 16 18 20
Average Weight 298 286 289 285 282 292 298 287 297 298 292
(+5%) 306 306 306 306 306 306 306 306 306 306 306 306 306 306 306 306 306 306 306 306
(-5%) 277 277 277 277 277 277 277 277 277 277 277 277 277 277 277 277 277 277 277 277
260
265
270
275
280
285
290
295
300
305
310
W
e
ig
h
t 
(m
g
)
Time (min.)
Average weight
Average Weight
(+5%)
(-5%)
 
0 2 4 6 8 10 12 14 16 18 20
Average Thickness 2,984 2,958 2,96 2,946 2,933 2,970 2,98 2,996 2,975 2,978 2,955
2,900
2,920
2,940
2,960
2,980
3,000
3,020
Th
ic
kn
es
s 
(m
m
)
Time (min.)
Average Thickness
 
0 2 4 6 8 10 12 14 16 18 20
Average Hardness 229,25 186,65 203,2 187,15 177,05 213,95 229,75 209,95 240,45 241,85 224,9
150
170
190
210
230
250
H
a
rd
n
e
s
s
 (
N
)
Time (min.)
Average Hardness
Multivariate analysis of a direct compression pharmaceutical tablets continuous manufacturing process. 
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0 2 4 6 8 10 12 14 16 18 20
Average Weight 269 291 289 296 291 289 291 293 288 299 293
(+5%) 304 304 304 304 304 304 304 304 304 304 304 304 304 304 304 304 304 304 304 304
(-5%) 275 275 275 275 275 275 275 275 275 275 275 275 275 275 275 275 275 275 275 275
250
260
270
280
290
300
310
W
ei
gh
t 
(m
g)
Time (min.)
Average weight
Average Weight
(+5%)
(-5%)
 
0 2 4 6 8 10 12 14 16 18 20
Average Thickness 2,9 2,961 2,956 2,967 2,959 2,945 2,962 2,962 2,951 2,973 2,962
2,86
2,88
2,9
2,92
2,94
2,96
2,98
Th
ic
kn
es
s (
m
m
)
Time (min.)
Average Thickness
 
0 2 4 6 8 10 12 14 16 18 20
Average Hardness 149,05 231,6 226,05 250,75 231,3 223,4 229,4 233,6 224,45 258,75 233,8
100
120
140
160
180
200
220
240
260
280
H
a
rd
n
es
s 
(N
)
Time (min.)
Average Hardness
